Article Text

Download PDFPDF
Post-exposure HIV prophylaxis following sexual exposure: a retrospective audit against recent draft BASHH guidance
  1. S Day,
  2. A Mears,
  3. K Bond,
  4. R Kulasegaram
  1. Lydia Department, Guy’s and St Thomas’s Hospitals, London SE1 7EH, UK
  1. Correspondence to:
 Dr R Kulasegaram
 Lydia Department, St Thomas’s Hospital, Lambeth Palace Road, London SE1 7EH, UK; doctor_saraday{at}yahoo.co.uk

Abstract

Objectives: To retrospectively audit the management of post-exposure HIV prophylaxis following sexual exposure (PEPSE) against the British Association for Sexual Health and HIV 2004 draft guidance.

Methods: A retrospective review of case notes from January 2000 to November 2004. The draft guidelines were not adopted into clinical practice during the study period.

Results: 76 patients received PEPSE. 79% (95% CI 68.08 to 87.46) of PEPSE prescriptions were given for exposures that were in accordance with the guidelines’ recommended indications (target 90%). 87% (95% CI 77.13 to 93.51) of PEPSE was prescribed within 72 hours of risk exposure (target 90%). 91% (95% CI 81.94 to 96.22) of recipients received a recommended antiretroviral combination. 53% (95% CI 40.84 to 64.21) of recipients completed the PEPSE course (target 75%). 45% of patients attended for the 3 month follow up HIV test but only 12% (95% CI 5.56 to 21.29) attended for both the 3 month and 6 month HIV test (target 75%).

Conclusion: PEPSE is predominantly being prescribed for recommended indications and is dispensed within 72 hours of risk exposure. PEPSE completion rates and attendance for 3 months and 6 months post-exposure HIV testing need improving, perhaps by introducing a PEPSE clinic.

  • BASHH, British Association for Sexual Health and HIV
  • PEP, post-exposure prophylaxis
  • PEPSE, post-exposure HIV prophylaxis following sexual exposure
  • post-exposure prophylaxis
  • HIV

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Conflict of interest: The authors have received financial assistance from pharmaceutical companies.